Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00977522 · ClinicalTrials.gov registry record · Phase 2
A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 207
- Enrollment target
NCT00977522 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 207 participants.
The verdict
NCT00977522, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 207 participants
- Enrollment target
Study Summary
This study is examining the efficacy of PF-03463275 compared to placebo in treating negative symptoms of schizophrenia when added to ongoing antipsychotic treatment in stable outpatients with schizophrenia.
Interventions
- DRUG Placebo
- DRUG PF-03463275
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 207 participants |
| Start Date | 2009-11 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00977522
The ClinicalTrials.gov registry entry for NCT00977522 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 207 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00977522 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00977522 about?
NCT00977522 is a clinical study titled "A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia". This study is examining the efficacy of PF-03463275 compared to placebo in treating negative symptoms of schizophrenia when added to ongoing antipsychotic treatment in stable outpatients with schizophrenia.
What is the current status of trial NCT00977522?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 207 participants. The study started on 2009-11. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00977522?
The interventions under investigation include: Placebo (DRUG), PF-03463275 (DRUG).
Who is sponsoring clinical trial NCT00977522?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.